MediGene AG · LS:A40ESG

MediGene — H1 2011 Earnings Presentation

19 slides from MediGene's earnings presentation, Aug 2, 2011

  1. Slide 1: Analyst Conference Call Financial Results 6-Months 2011

    Analyst Conference Call Financial Results 6-Months 2011 August 2, 2011 Dr. Frank Mathias, Chief Executive Officer Arnd Christ, Chief Financial Officer

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila

  3. Slide 3: Recent achievements

    Recent achievements

  4. Slide 4: Successful first half of 2011

    Successful first half of 2011  Positive financial results 6M 2011  Eligard® rights for EU countries transferred to Astellas; milestone payment of € 15 million received  Veregen® approved in Spain, pricing approval granted in Austria  Conclusion of new Veregen® partnership agreements  RhuDex®: N

  5. Slide 5: Veregen commercialization is progressing

    Veregen® commercialization is progressing  Increasing in-market sales in USA, Germany, and Austria  Approved in Spain, market launch planned for 2012  Reimbursement approval in Austria since June 2011  During first half of 2011, new marketing partnerships secured across Europe, America and Asia

  6. Slide 6: RhuDex: Resumption of clinical development planned

    RhuDex: Resumption of clinical development planned  Preclinical studies conducted have led to • Identification of prefered pharmacokinetic profile • New formulation strategy developed to optimise exposure during chronic treatment  Plan to prepare for further clinical development finalized: • to t

  7. Slide 7: New formulation strategy to optimize exposure during chronic treatment

    New formulation strategy to optimize exposure during chronic treatment Plasma Level* Daily Dose Efficacy level Plasma Level* Improvement Daily Dose * schematic demonstration 7

  8. Slide 8: AAVLP: Development collaboration with The Johns Hopkins University

    AAVLP: Development collaboration with The Johns Hopkins University  Objective: Test vaccine candidates derived from the AAVLP program for the prevention of HPV-associated cancer types  Vaccine candidates to be tested against a number of carcinogenic human papillomaviruses (HPV) causing, for exampl

  9. Slide 9: Financial results

    Financial results

  10. Slide 10: Positive results 6M 2011

    Positive results 6M 2011  Increased revenue (from continued and discontinued operations) of € 29.6 million, including revenue from milestone payments of € 20 million from Astellas  Veregen® revenue from product sales and royalties increased by 43%  Positive EBITDA of € 17.0 million  Positive net

  11. Slide 11: Revenue increase driven by Eligard and Veregen

    Revenue increase driven by Eligard and Veregen In € million  Eligard®: Revenue from continued and discontinued operations • Milestones of € 20 million from Astellas 29.6 included in revenue from discontinued 25.2 operations 13.2 -88% 2010 18% • Since March 2011 royalty stream of 2% 2011 1.6 accou

  12. Slide 12: R&D and SG&A expenses further reduced

    R&D and SG&A expenses further reduced In € million Research and development costs 7.5  Effects from restructuring measures: 3.4 -55% 3.6 2010 1.5 2011 • Personnel : -46% -52% • Third-party expenses: -76% Q2 6M Selling, general and administrative expenses (continued and discontinued) 4.7 3.8  Savin

  13. Slide 13: High revenues lead to positive results 6M 2011

    High revenues lead to positive results 6M 2011 In € million  Positive EBITDA and net result EBITDA Q2 6M  Impact of strategic measures taken 17.0 in 2010 2010 • One-time milestone payments from 2011 transfer of Eligard rights lead to high revenues -3.0 -2.2 -5.4 • Cost saving measures become Resu

  14. Slide 14: Milestone payment for transfer of Eligard rights increased cash balance

    Milestone payment for transfer of Eligard rights increased cash balance In € million -0.1 0 -0.3 11.5 15.9 4.8 Cash balance Cash flow from Cash flow from Cash flow from Foreign Cash balance Jan. 1, 2011 operating activities investing activities financing activities exchange Jun. 30, 2011 difference

  15. Slide 15: Outlook

    Outlook

  16. Slide 16: Financial outlook 2011 – confirmation of guidance

    Financial outlook 2011 – confirmation of guidance  Revenues* • From continued and discontinued operations: € 32-38 million • Thereof one-time milestone payments for Eligard® totaling € 20-25 million − € 20 million already recognized in March 2011 − € 5 million to be recognized 2011/2012  EBITDA* •

  17. Slide 17: Project objectives

    Project objectives  Eligard ® • Transfer of rights for non-EU countries to Astellas  Veregen® • Submission of additional market approval applications in Europe • Conclusion of further marketing partnership agreements  EndoTAG®-1 • Achieve global or regional licenses for the further development of

  18. Slide 18: Q&A

    Q&A Frank Mathias, CEO & Arnd Christ, CFO

  19. Slide 19: MediGene AG contact details

    MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com

MediGene — H1 2011 Earnings Presentation on 6ix